drugset / Trial / NCT00647972

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

NCT00647972

Phase 1 Terminated 32 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.

Timeline

Start
2003-05
Primary completion
2003-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 20 mg Oral

Indications

No indication recorded.